Clinical Trials Logo

Clinical Trial Summary

Optic Neuritis (ON) is a condition that occurs in approximately 50% of individuals with relapse remitting MS, and is the presenting event in 15-20% of patients who go on to develop MS. These ON events present with a decline in vision over several days with painful eye movements. The purpose of this study is to collect pilot data on the effect of Fampridine-SR on the recovery of visual function after demyelinating optic neuritis.Our team evaluated a person with ON who had incomplete recovery which was quite bothersome to her. After a one-month treatment course Fampridine SR,her visual functioning improved. Based on this case, we present a unique opportunity to evaluate the potential benefit of Fampridine-SR as a potential treatment for persons who do not fully recover from acute ON.


Clinical Trial Description

Optic Neuritis (ON) is a condition that occurs in approximately 50% of individuals with relapse remitting MS, and is the presenting event in 15-20% of patients who go on to develop MS. ON usually presents with a decline in vision over several days to weeks with painful eye movements. Fampridine-SR is currently a Health Canada approved medication to treat walking impairment in persons with MS. Some small studies in the past have shown that Fampridine-SR may also have positive effects on visual functioning in those experiencing ON. This study will aim to assess the effect of taking Fampridine-SR for 8 weeks in 20 MS patients with unresolved optic neuritis on measures of visual functioning, and to determine the best measures to use in a future large scale study. The results of this study will also be used to estimate how many participants we will need in the future large scale study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04148781
Study type Interventional
Source London Health Sciences Centre
Contact Heather Rosehart, BSc
Phone 519-685-8500
Email heather.rosehart@lhsc.on.ca
Status Recruiting
Phase Early Phase 1
Start date March 22, 2022
Completion date January 2024

See also
  Status Clinical Trial Phase
Unknown status NCT00261326 - Simvastatin Treatment of Patients With Acute Optic Neuritis Phase 3
Active, not recruiting NCT03963310 - Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
Recruiting NCT03586557 - Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis N/A
Recruiting NCT05487989 - VIsual Pathways Model in Neuro-inflammatory Disorders
Terminated NCT04131764 - Diagnosis of ON With or Without MS or NMOSD
Not yet recruiting NCT06453694 - Efgartigimod for the Treatment of Acute Optic Neuritis Phase 2
Completed NCT01962571 - Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Phase 3
Recruiting NCT03302585 - High-Dose Vitamin D Induction in Optic Neuritis Phase 2
Recruiting NCT02886377 - The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset N/A
Completed NCT01987167 - Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis Early Phase 1
Completed NCT01451593 - Neuroprotection With Phenytoin in Optic Neuritis Phase 2
Completed NCT03630497 - BN201 SAD MAD Study in Healthy Subjects Phase 1
Completed NCT01337986 - Ampyra for Optic Neuritis in Multiple Sclerosis Phase 2/Phase 3
Completed NCT01274702 - Visual Reconstitution Therapy After Optic Neuritis Phase 2
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Withdrawn NCT00037115 - Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Phase 4
Not yet recruiting NCT06389968 - Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis N/A
Recruiting NCT04257734 - Epidemiologic and Clinical Characteristics of Optic Neuritis in China
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Completed NCT02939937 - Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis Phase 2